The approval is based on a phase 2 trial showing that Libtayo achieved a response in 29% of patients ... although the picture may not be quite so simple. On its own, Keytruda cut the risk of ...
Researchers at the Tandon School of Engineering will develop an artificial intelligence-powered simulation system that can ...
The presentation will feature updates from the San Diego County Sheriff and Robert Logan, fire chief of the San Diego Fire-Rescue Department, on emergency response procedures, actions to increase ...
Ferrari posted a picture of Hamilton reclining on two tires with their helmet in his left hand. The post was captioned as: Kyle Larson, the #5 for Hendrick Motorsports had a remarkable 2024 where ...
Lady Gaga has responded to critics of Joker: Folie a Deux (Picture: Axelle/Bauer-Griffin/FilmMagic) A follow-up to the hit 2019 film Joker, the comic book sequel ...
The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed ...
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback